Last reviewed · How we verify
Placebo pressurized metered dose inhaler
A placebo pressurized metered dose inhaler delivers no active pharmaceutical ingredient, serving as a control comparator in clinical trials.
A placebo pressurized metered dose inhaler delivers no active pharmaceutical ingredient, serving as a control comparator in clinical trials. Used for Clinical trial control comparator (non-therapeutic use).
At a glance
| Generic name | Placebo pressurized metered dose inhaler |
|---|---|
| Sponsor | Actavis Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo inhalers are inert formulations used in randomized controlled trials to establish the efficacy of active respiratory medications through comparison against a non-therapeutic control. They mimic the physical delivery mechanism and patient experience of active inhalers without containing any pharmacologically active drug substance, allowing researchers to isolate the true therapeutic effect from expectancy and device effects.
Approved indications
- Clinical trial control comparator (non-therapeutic use)
Common side effects
Key clinical trials
- A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). (PHASE3)
- Reversibility of Methacholine Induced Bronchoconstriction (PHASE4)
- Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR® (PHASE1)
- A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV) (PHASE1)
- A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma (PHASE3)
- CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD (PHASE4)
- Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma (PHASE3)
- Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo pressurized metered dose inhaler CI brief — competitive landscape report
- Placebo pressurized metered dose inhaler updates RSS · CI watch RSS
- Actavis Inc. portfolio CI